Abstract:Abstract The human epidermal growth factor receptor (EGFR) is expressed at high levels in at least 20% of breast cancers overall, but in 60-70% of patients with triple-negative breast cancer (TNBC), which makes EGFR a potential treatment target. Herein we developed a novel therapy for TNBC that utilizes anti-EGFR monoclonal antibody (mAb)-conjugated nanodiamonds (NDs) to specifically deliver paclitaxel (PTX) to breast cancer cells over-expressing EGFR. NDs, 2-8 nm diameter carbon nanoparticles, have recently emerged as promising drug carriers. In this study, we have synthesized a versatile ND construct that incorporates anti-EGFR mAb, fluorescent imaging agent and paclitaxel for multimodal imaging, targeting and treatment of TNBC. Sulfo-LC-SPDP was attached on to an aminated ND surface (ND-NH2), yielding sulfhydryl-reactive NDs (ND-SPDP). Thiolated paclitaxel-oligonucleotide (PTX-DNA) conjugates and thiolated mAbs were then simultaneously attached to ND-SPDPs, forming PTX-DNA/mAb@NDs. For the PTX-DNA conjugate, a fluorescein-labeled dT-nucleotide was inserted within the thiolated 20-mer poly-dT strand for cellular imaging and PTX loading quantification. The resultant nanoparticles could form highly stable suspensions in aqueous solutions. Dithiothreitol treatment detaches PTX-DNA and thiolated mAbs from the ND surface. About 2.2 ± 0.4 nmol of PTX and 53.5 ± 2.1 µg of mAb were loaded on per mg of PTX-DNA/mAb@NDs, while 3.1 ± 0.7 nmol of PTX for per mg of PTX-DNA@NDs. The targeting capacity of PTX-DNA/mAb@NDs was tested through flow cytometry analysis and confocal microscopy within 2 breast cancer cells of contrasting EGFR expression. Internalization of PTX-DNA@NDs and PTX-DNA/mAb@NDs was nearly equivalent within basal EGFR expressing MCF7 cells. However, when EGFR-overexpressing MDA-MB-231 cells were treated with PTX-DNA/mAb@NDs, there was a nearly 150% enhancement in the fluorescence signal as compared to that of PTX-DNA@NDs. Internalization of anti-EGFR-conjugated NDs within MDA-MB-231 cells was competitively inhibited by the addition of EGF. MTT assays were performed comparing free PTX with untargeted and targeted versions of PTX-DNA@NDs at equivalent PTX dosages in both cells. Enhanced cytotoxicity was observed in escalating-dose studies after 48 h treatment of PTX-DNA@NDs and PTX-DNA/mAb@NDs across all concentrations. Within MDA-MB-231 cells, anti-EGFR linked conjugates had an IC50 value of 43.8 nM, a nearly two-fold increase in efficacy compared to untargeted conjugates (83.3 nM). The data suggests that targeting through the mAb moiety increases specificity and internalization, which subsequently enhances therapeutic activity. Intravenous injection of NDs (up to 1.2 mg) didn't induce any toxicity and systemic immune response in mice, attesting to NDs as a biocompatible nanocarrier platform. In vivo efficacy of PTX-DNA/mAb@NDs will be further investigated in tumor-bearing mice. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1962. doi:1538-7445.AM2012-1962

Near-infrared Photothermal Therapy Using Anti-Egfr-gold Nanorod Conjugates for Triple Negative Breast Cancer

Gold nanorod embedded large-pore mesoporous organosilica nanospheres for gene and photothermal cooperative therapy of triple negative breast cancer.

Tumor oxygenation nanoliposomes promote deep photodynamic therapy for triple-negative breast cancer

Near-Infrared Titania Nanoparticle-Based Photoimmunotherapy Via Tumor-Microenvironment-Responsive Gene Editing of SerpinB9 for Triple-Negative Breast Cancer

Fisheries science. Miscue raises doubts about survey data.

Injectable Alginate Complex Hydrogel Loaded with Dual-Drug Nanovectors Offers Effective Photochemotherapy against Triple-Negative Breast Cancer

Metal-phenolic-network-coated Gold Nanoclusters for Enhanced Photothermal/chemodynamic/immunogenic Cancer Therapy

Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals

Abstract 1962: Engineering of EGFR-targeted Nanoparticles for Triple Negative Breast Cancer Therapy

Monitoring of intrasplenic hepatocyte transplantation for acute-on-chronic liver failure: a prospective five-year follow-up study.

Tumor Cell Targeting and Responsive Nanoplatform for Multimodal-Imaging Guided Chemodynamic/Photodynamic/Photothermal Therapy toward Triple Negative Breast Cancer

Gold nanoplatform for near-infrared light-activated radio-photothermal gas therapy in breast cancer

Gulf War Syndrome, Chronic Fatigue Syndrome, and the Multiple Chemical Sensitivity Syndrome: stirring the cauldron of confusion.

Co‐delivery CPT and PTX prodrug with a photo/thermo‐responsive nanoplatform for triple‐negative breast cancer therapy

Gold Nanobipyramids for Near-Infrared Fluorescence-Enhanced Imaging and Treatment of Triple-Negative Breast Cancer

A Multifunctional Nanoplatform for Ultrasound Imaging and Autophagy Inhibition to Enhance Photothermal Treatment of Triple Negative Breast Cancer

Anti-EGFR Peptide-Conjugated Triangular Gold Nanoplates for Computed Tomography/Photoacoustic Imaging-Guided Photothermal Therapy of Non-Small Cell Lung Cancer

Self-assembled albumin nanoparticles induce pyroptosis for photodynamic/photothermal/immuno synergistic therapies in triple-negative breast cancer

Synergistic Effects of Photodynamic Therapy and Chemotherapy: Activating the Intrinsic/extrinsic Apoptotic Pathway of Anoikis for Triple-Negative Breast Cancer Treatment

Dual-Targeting Tumor and Subcellular Endoplasmic Reticulum via AgPPIX-based Janus Nanoparticles for Photodynamic/Immunotherapy against TNBC

Near Infrared Light Mediated Photochemotherapy for Efficiently Treating Deep Orthotopic Tumors Guided by Ultrasound Imaging.